ROBERT MIMS: Open Payments
NPI 1851303135 · ARLINGTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,519 in 57 payments from 6 companies in 2025. Trend: 2023 $1,044 · 2024 $987 · 2025 $1,519
Food & beverage: $1,519
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 23 | $477 |
| E.R. Squibb & Sons, L.L.C. | 10 | $307 |
| Janssen Pharmaceuticals, Inc | 10 | $297 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $214 |
| Otsuka America Pharmaceutical, Inc. | 1 | $113 |
| Lundbeck LLC | 5 | $111 |
Products named: UZEDY, COBENFY, INVEGA SUSTENNA, CAPLYTA, ABILIFY MAINTENA, ABILIFY ASIMTUFII, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
